Abstract

Simple SummaryHPV vaccination protects against virus that may cause cervical cancer. Opportunistic HPV vaccination (i.e., vaccination at a citizens’ own initiative and cost) has been available in Norway since the first HPV vaccine was licensed in 2006. A routine HPV vaccination program targeting 12-year-old girls was introduced in 2009. A delayed catch-up vaccination program was initiated in 2016, offering HPV vaccination free-of-charge to women born in 1991 and later who had not previously been vaccinated in the routine program. The aim of this study was to assess sociodemographic correlates of opportunistic and catch-up HPV vaccine uptake among women in Norway. We found inequalities in both self-paid opportunistic and free-of-charge catch-up HPV vaccine uptake among adolescents and adult women, with particularly low uptake among women with two immigrant parents and among women with a low household income.Achieving equity in human papillomavirus (HPV) vaccination has high priority. In this nationwide registry-based study, we aimed to investigate sociodemographic correlates of HPV vaccine uptake among women who were vaccinated opportunistically at their own initiative and cost during October 2006–June 2018, and among women who were vaccinated free-of-charge in a catch-up vaccination program during November 2016–June 2018. For 840,328 female residents born in Norway between 1975 and 1996, we retrieved HPV vaccination and sociodemographic data from national registries. We used separate models to analyze the sociodemographic correlates of the initiation and completion of HPV vaccination in opportunistic and catch-up vaccination settings. Overall initiation rate for opportunistic HPV vaccination was 2.2%. Uptake increased consistently with birth year, maternal education level, and household income. Having two immigrant parents or a mother working in a lower prestige occupation was strongly associated with low opportunistic vaccination uptake. Similar but weaker inequities were observed in catch-up HPV vaccination. Initiation rate during the first 20 months of the catch-up program was 46.2%. Completion rate was 72.1% and 73.0% for opportunistic or catch-up vaccination, respectively, with small inequities. In conclusion, HPV vaccine uptake was strongly associated with sociodemographic background both in opportunistic and catch-up vaccination settings, with particularly low uptake associated with having two immigrant parents and low household income.

Highlights

  • Human papillomavirus (HPV) has a predilection for infecting cutaneous and mucosal epithelial cells and subsequently causes almost all cervical cancer and a substantial fraction of other anogenital and oropharyngeal cancers [1,2]

  • Among the 201,326 women eligible for catchup vaccination during the study period, 92,913 had at least one dose of the 2v vaccine, resulting in an initiation rate of 46.2% during the first 20 months of the catch-up program

  • Several sociodemographic characteristics were strongly associated with uptake of opportunistic human papillomavirus (HPV) vaccination with the lowest initiation and completion rates observed among women in older birth cohorts, women with two immigrant parents, women with mothers with the lowest education, and women living in households with the lowest income

Read more

Summary

Introduction

Human papillomavirus (HPV) has a predilection for infecting cutaneous and mucosal epithelial cells and subsequently causes almost all cervical cancer and a substantial fraction of other anogenital and oropharyngeal cancers [1,2]. Vaccination against HPV has a high potential to improve public health. HPV6, 11, 16, 18 and a nonavalent (9v) vaccine against HPV6, 11, 16, 18, 31, 33, 45, 52, 58. All HPV vaccines have proven to be safe, highly immunogenic, and effective against vaccine-type HPV infection and high-grade cervical lesions in clinical trials [5]. The HPV vaccines are prophylactic, and most effective if given to HPV-naïve individuals. Catch-up vaccination of older birth cohorts may be cost-effective, the value for money generally decreases with increasing age at vaccination and the upper age limit for a cost-effective intervention varies greatly between studies, depending on setting, model type, and underlying assumptions [6]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call